Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-05 21:08:30时区推断·⟳ 抓取 08-05 21:09:09·⚡ 决策 08-06 03:15:56 +6h06m·83.1 天前
中国苏轩堂药业将实施1并80反向拆股
1并80反向拆股本身只是股本合并，不改变公司收入、利润、现金流或资产价值，缺少可量化基本面催化。
📄 原文Investing.com↗ 原文
China SXT Pharmaceuticals to implement 1-for-80 reverse stock split
Our AI knew it: This high-conviction medtech just jumped 27%+ on blowout earnings TAIZHOU, China - China SXT Pharmaceut…
不做 中国苏轩堂药业（SXTC.US）
反向拆股不改变基本面价值，虽有低价合规压力的负面信号，但缺少明确、强的公司级净损害，不满足做空红线；当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-05 · 扩散 low · price-in 风险 medium ↗
关键理由
- 1并80反向拆股本身只是股本合并，不改变公司收入、利润、现金流或资产价值，缺少可量化基本面催化。
- 该事件更像纳斯达克低价合规压力下的资本结构处理，方向偏负但不够强，不能单独构成高置信做空催化。
主要风险
- 微盘中概药企反向拆股后波动和流动性风险很高，价格行为可能被盘口和并股技术因素主导。
原文全文
展开原文 · 1,500 字
Our AI knew it: This high-conviction medtech just jumped 27%+ on blowout earnings
TAIZHOU, China - China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) announced a 1-for-80 reverse stock split of its Class A and Class B ordinary shares, effective August 10, 2026, according to a press release statement.
The company’s Class A ordinary shares will begin trading on a post-consolidation basis at the market opening on August 10, 2026, on The Nasdaq Stock Market under the existing symbol SXTC with a new CUSIP number G2161P173.
Prior to the share consolidation, 105,704,077 Class A ordinary shares are issued and outstanding. Following the consolidation, every 80 shares will be combined into one share, with fractional shares rounded up to the next whole share, resulting in approximately 1,321,301 Class A ordinary shares outstanding.
All outstanding stock options, warrants and other rights to purchase the company’s Class A ordinary shares will be adjusted proportionately as a result of the share consolidation.
Shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the consolidation. The company’s transfer agent is Transhare Corporation.
China SXT Pharmaceuticals is a pharmaceutical company based in Taizhou City, Jiangsu Province, China, focused on traditional Chinese medicine pieces. The company was founded in 2005.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TAIZHOU, China - China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) announced a 1-for-80 reverse stock split of its Class A and Class B ordinary shares, effective August 10, 2026, according to a press release statement.
The company’s Class A ordinary shares will begin trading on a post-consolidation basis at the market opening on August 10, 2026, on The Nasdaq Stock Market under the existing symbol SXTC with a new CUSIP number G2161P173.
Prior to the share consolidation, 105,704,077 Class A ordinary shares are issued and outstanding. Following the consolidation, every 80 shares will be combined into one share, with fractional shares rounded up to the next whole share, resulting in approximately 1,321,301 Class A ordinary shares outstanding.
All outstanding stock options, warrants and other rights to purchase the company’s Class A ordinary shares will be adjusted proportionately as a result of the share consolidation.
Shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the consolidation. The company’s transfer agent is Transhare Corporation.
China SXT Pharmaceuticals is a pharmaceutical company based in Taizhou City, Jiangsu Province, China, focused on traditional Chinese medicine pieces. The company was founded in 2005.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。